- Poster Presentation
Insulin-like growth factor signalling in oestrogen nonresponsive breast cancer cells
Breast Cancer Research volume 8, Article number: P16 (2006)
Insulin-like growth factors (IGFs) regulate normal growth and development. In breast cancer, they stimulate cell proliferation, cell migration and inhibit apoptosis. The IGF signal transduction pathway is, therefore, a potential therapeutic target in the treatment of breast cancer [1, 2]. Inhibitors of the IGF pathway may be effective in the treatment of breast cancer with de novo or acquired endocrine resistance. We have studied IGF signalling in oestrogen nonresponsive MDA-MB-231, HBL-100 and BT-20 breast cancer cell lines as models of endocrine resistant breast cancer. Oestrogen responsive MCF-7 cells were also studied.
Components of the IGF signalling pathway, type I IGF Receptor (IGF1R), IRS-1, IRS-2, and the three Shc isoforms, were expressed at varying levels, demonstrating a range of phenotypes in the breast cancer cells. IRS-1 is expressed in a truncated form in the BT-20 cells as an antibody to the C-terminus is unable to detect the protein.
IGF-1 activated IGF1R, IRS-1, MAP kinase and Akt in the MCF-7, MDA-MB-231 and HBL-100 cell lines. IGF-1 stimulated phosphorylation of IGF1R in BT-20 cells but did not alter the level of activation of IRS-1, MAP kinase or Akt. The MEK1/2 inhibitor (PD 98059) and the PI-3 kinase inhibitor (LY 294002) decreased the level of phosphorylation of MAP kinase and Akt in BT-20 cells. A phosphospecific antibody to tyrosine 896, the Grb2 SH2 binding site, shows that IRS-1 is constitutively phosphorylated in BT-20 cells.
IGF-1 inhibited staurosporine-induced apoptosis in MCF-7, MDA-MB-231 and HBL-100 cells but not in BT-20 cells. Inhibition of the IGF signalling pathways with PD 98059 and LY 294002 sensitise MDA-MB-231 cells to staurosporine-induced apoptosis. IGF-1 stimulated growth in MCF-7 and MDA-MB-231 cells but not in BT-20 cells.
Expression and activation of IGF signalling proteins vary among the oestrogen nonresponsive cells. These differences will affect the response of breast cancer cells to IGF targeted therapy. BT-20 cells provide a useful model for constitutive IRS-1 phosphorylation which is reported to occur in breast tumours .
Molloy CA, May FEB, Westley BR: Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem. 2000, 275: 12565-12571. 10.1074/jbc.275.17.12565.
Garber K: IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst. 2005, 97: 790-792.
Chang Q, Li Y, White MF, Fletcher JA, Xiao S: Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumours: therapeutic implications. Cancer Res. 2002, 62: 6035-6038.
This project was funded by Breast Cancer Campaign.
About this article
Cite this article
de Blaquiere, G., May, F. & Westley, B. Insulin-like growth factor signalling in oestrogen nonresponsive breast cancer cells. Breast Cancer Res 8, P16 (2006). https://doi.org/10.1186/bcr1571
- Endocrine Resistant Breast Cancer
- Endocrine Resistant Breast
- Nonresponsive Breast Cancer